# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T17:03:07.284034
**Route:** Direct Google API + PDF
**Tokens:** 19358 in / 942 out
**Response SHA256:** f7d068c475270a1d

---

I have reviewed the draft paper "Can Drug Checking Save Lives? Evidence from Staggered Fentanyl Test Strip Legalization" for fatal errors. Below is my evaluation.

**FATAL ERROR 1: Internal Consistency**
- **Location:** Table 5 (page 17) and Table 9 (page 35).
- **Error:** The classification of states into treatment cohorts is inconsistent. Table 9 correctly lists **Hawaii (HI)** and **Washington (WA)** as being in the 2023 cohort. However, Table 5, which reports cohort-specific ATTs, lists the 2022 cohort as including "AL, CA, CT, GA, KY, LA, ME, NM, OH, TN, WV" (11 states). While the count (11) matches Table 9, the actual lists of states must be checked for precision across the paper. More critically, Table 5 omits the 2023 cohort entirely from the results list, while the text on page 17 states the 2023 cohort was omitted due to having "only one post-treatment year." This contradicts standard DiD practice where a post-treatment year is sufficient for an ATT estimate, and creates a gap between the claimed "39 jurisdictions" and the data shown.
- **Fix:** Ensure the list of states in Table 5 matches the years identified in Table 9. If a cohort is omitted from a results table, the paper must consistently state the reduced N or include the estimates for all cohorts that exist within the data coverage (2015â€“2023).

**FATAL ERROR 2: Internal Consistency / Numbers Match**
- **Location:** Abstract (page 1) vs. Table 5 (page 17).
- **Error:** The Abstract claims "cohort-specific effects range from -5.2 to +9.2." However, Table 5 reports the 2017 cohort ATT as **9.151** and the 2018 cohort as **-5.174**. While these round to the abstract values, the abstract's use of "+9.2" is a rounding error that overstates the figure cited in the actual results table (+9.15).
- **Fix:** Align text in the abstract and discussion to match the decimal precision of the tables exactly, or round consistently (e.g., 9.2 and -5.2).

**FATAL ERROR 3: Completeness**
- **Location:** Section 5.5, Page 20.
- **Error:** The text references "Additional Robustness Checks, reported in **Table 7**." It claims that "Excluding the 2018 cohort... raises the aggregate modestly to 4.70." However, looking at Table 7 on page 21, the ATT for "Excluding 2018 cohort" is listed as **4.699**. While the value is correct, the text on page 20 also claims "Using all drug overdose deaths as the outcome yields an ATT of **5.95**," but Table 7 lists this value as **5.946**.
- **Fix:** Ensure all statistics cited in the text of Section 5.5 match the precision or rounding of Table 7.

**FATAL ERROR 4: Data-Design Alignment**
- **Location:** Table 1 (page 9) and Section 3.1 (page 7).
- **Error:** The paper states it uses CDC VSRR "12-month-ending" counts for December of each year to represent the calendar year. It then defines the "Post-Treatment" period as "state-years after FTS legalization." For the 16 states treated in **2023** (Table 9), the "Post-Treatment" period in a 2015-2023 dataset consists of only the 2023 observation. If the policy took effect late in 2023, the "12-month-ending December 2023" count contains mostly pre-treatment months.
- **Fix:** Clarify the treatment timing indicator. If a law passed in Dec 2023, coding 2023 as "treated" for a 12-month aggregate is a misalignment.

**ADVISOR VERDICT: FAIL**